Recent developments include Radnostix reporting its second-highest annual revenue in FY2025 with strong growth in Calibration & Reference Products and key product launches. The company mutually terminated an asset purchase agreement related to its uranium de-conversion assets in March 2026 and is evaluating options for these assets. Operational challenges and voluntary recalls impacted Q1 2026 results.

• Radnostix reported FY2025 results with the second-highest annual revenue in company history, driven by strong growth in Calibration & Reference Products and advancement of key product launches [N6].
• In March 2026, Radnostix mutually terminated the asset purchase agreement related to its DUF6 uranium de-conversion assets and is evaluating options for these assets [N7].
• Q1 2026 sales decreased approximately 27% compared to Q1 2025 due to voluntary recalls and operational shutdowns, including a shutdown for cobalt-60 hot cell gasket repairs [S2].
• The company continues to implement corrective actions following an FDA Official Action Indicated from an inspection in April 2025, with ongoing risk of further regulatory actions [S2].

Radnostix benefits from a diversified portfolio across nuclear medicine calibration, radiopharmaceuticals, cobalt products, and medical devices. The company has demonstrated operational capabilities with FDA-approved products and ongoing product development in medical devices. Its domestic manufacturing of cobalt-60 and unique licensing status provide competitive advantages. Recent FY2025 results showed strong growth in Calibration & Reference Products and advancement of key product launches. The company is actively managing supply chain challenges and regulatory compliance, positioning it to serve growing markets in theranostics and nuclear medicine.

The company faces significant risks from supply chain disruptions due to reliance on just-in-time delivery of critical radioisotopes, some sourced internationally or from specialized reactors with planned maintenance outages. Recent voluntary product recalls have impacted sales and profitability. Liquidity ratios indicate moderate constraints, and the company carries multiple promissory notes with accrued interest. Regulatory risks include ongoing FDA corrective actions and NRC license enforcement requirements. The termination of the DUF6 asset sale introduces uncertainty regarding the future of those assets. Market competition and operational challenges in product development and manufacturing also pose risks to business stability.

Radnostix's competitive advantages include its unique position as the only domestic manufacturer of finished cobalt-60 sources in the U.S., with sole sourcing from the Idaho National Lab. The company's FDA-approved generic sodium iodide I-131 product offers a domestic alternative to foreign manufacturers. Its high energy and high activity NRC licensing status permits handling of specialized radioisotopes, supported by compliance with cGMP and an FDA-licensed facility. The company's ownership of RadQual and experienced personnel in regulatory and manufacturing processes further strengthen its market position. These factors contribute to barriers for new entrants and provide a differentiated product offering in a highly regulated industry.

• Supply Chain Disruptions: The company relies on a just-in-time supply chain for radioisotopes, which are sourced globally and from specialized reactors. Disruptions can cause product loss, revenue decline, and impact patient care and clinical trials.
• Regulatory Compliance Risks: Radnostix is subject to FDA and NRC regulations, including cGMP requirements and facility inspections. Recent FDA Official Action Indicated requires corrective actions, with potential for further enforcement including penalties or operational holds.
• Product Recalls Impact: Voluntary recalls in early 2026 of Generic Sodium Iodide I-131 and Dibasic Sodium Phosphate Capsules have led to lost sales, customer credits, and inventory write-offs, affecting financial performance.
• Liquidity and Financial Obligations: Liquidity ratios as of March 31, 2026, show a current ratio below 1 and cash ratio of 0.3, indicating moderate liquidity constraints. The company has multiple promissory notes with extended maturities and accrued interest, which may impact financial flexibility.
• Operational Risks in Manufacturing: Shutdowns for maintenance and repairs, such as the cobalt-60 hot cell gasket rehabilitation, have caused significant sales declines and increased costs. Product development in medical devices is in early stages with associated risks.

• Radnostix Inc. is a U.S.-based company headquartered in Idaho Falls, Idaho, operating in the nuclear medicine and radiopharmaceutical industry [S1].
• The company operates through five reportable segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products [S2].
• Theranostics Products is the largest revenue segment, producing an FDA-approved generic sodium iodide I-131 drug for hyperthyroidism and thyroid cancer treatment, radiochemicals for clinical research, and cGMP Active Pharmaceutical Ingredients for third-party clients [S2].
• Cobalt Products segment manufactures cobalt-60 products for medical, research, and industrial applications, including sealed sources for radiation therapy and recycling of expended cobalt-60 sources [S2].
• Calibration & Reference Products segment produces sealed source calibration and reference standards used in nuclear pharmacies, imaging clinics, laboratories, and industrial settings; it also sells bulk isotopes and related shielding and accessories [S2].
• Medical Devices segment sells third-party products and develops proprietary devices, including an I-131 encapsulation system and RadVent devices, with product releases targeted around 2026-2027 [S2].
• Fluorine Products segment is evaluating fundraising, joint ventures, or divestiture of assets related to fluorine gases and a planned uranium de-conversion facility; a prior asset sale agreement was mutually terminated in March 2026 [S2, N7].
• The company owns 100% of RadQual, LLC, a global supplier of molecular imaging quality control and calibration devices, and wholly owns TI Services, LLC, a 50/50 joint venture with RadQual [S2].
• Radnostix is the only domestic manufacturer of finished cobalt-60 sources, sourcing cobalt-60 solely from the Idaho National Lab, with supply coordination through the U.S. Department of Energy [S2].
• The company faces supply chain risks due to reliance on just-in-time delivery of radioisotopes, some sourced internationally, with potential disruptions from geopolitical, regulatory, or operational issues [S2].
• There have been recent voluntary recalls in early 2026 affecting Generic Sodium Iodide I-131 and Dibasic Sodium Phosphate Capsules, impacting sales and resulting in customer credits and inventory write-offs [S2].
• The company reported a net loss of $1,348,086 for Q1 2026, compared to a net loss of $112,694 in Q1 2025, driven by lost sales from recalls and operational shutdowns [S2].
• Sales decreased approximately 27% in Q1 2026 compared to Q1 2025, with declines in Theranostics, Cobalt Products, and Calibration & Reference Products segments [S2].
• Cobalt Products sales dropped 87% in Q1 2026 due to shutdown for hot cell window gasket repairs, which were completed by end of March 2026 [S2].
• Calibration & Reference Products sales decreased 33% in Q1 2026 due to prior pent-up demand in 2025 and ongoing global shortages of gadolinium-153 isotope [S2].
• Medical Devices segment sales increased 69% in Q1 2026 compared to Q1 2025, reflecting early-stage growth and product development [S2].
• The company had cash and cash equivalents of approximately $1.35 million as of March 31, 2026, with a current ratio of 0.88 and cash ratio of 0.3, indicating liquidity constraints [S2].
• Radnostix has multiple promissory notes with maturity dates extended to 2028, with accrued interest payable, and some notes secured by company assets [S2].
• The company is subject to FDA and NRC regulations, including cGMP compliance and regular inspections; recent FDA inspection resulted in an Official Action Indicated with ongoing corrective actions [S2].
• The company faces risks from supply chain disruptions, regulatory compliance, and reliance on specialized nuclear reactors for isotope supply, including planned maintenance at the Advanced Test Reactor in 2027 [S2].
• The Board of Directors consists of experienced members with expertise in nuclear medicine, finance, and management, including the CEO Shahe Bagerdjian appointed in 2023 [S1].
• Recent news highlights include the FY2025 report of second-highest annual revenue in company history with strong growth in Calibration & Reference Products and key product launches [N6].
• The company mutually terminated the asset purchase agreement related to the DUF6 assets in March 2026 and is evaluating options for these assets [N7].